
Conavi Medical closes $12-million public offering
Conavi Medical closes $12-million public offering

Conavi Medical closes $12-million public offering
Diagnos talks regulatory progress for CARA
Netramark arranges $3.5-million private placement
Briacell Therapeutics has success with Bria-OTS patient
Cardiol eclipses 50% patient enrolment in Maveric trial
Conavi Medical Corp. Announces Closing of $12M Public Offering
Thiogenesis Therapeutics' MELAS Abstract Accepted for Late-Breaking News Presentation at Mitocon 2026
DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress
University of California Berkeley and Glass House Collaboration Leads to State-Funded Research on Cannabis Crop Yields
BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS(TM) Patient
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Nxera Pharma to Receive US$3.6 Million in Milestone Payment Pursuant to Research Collaboration with Centessa
Profound's Dec. 31 Tulsa-Pro installed base at 78
Theralase, Ferring sign clinical development agreement
TempraMed Closes C$2.5 Million Fully Subscribed Private Placement